FDA Accepts Genentech’s New Drug Application for Xofluza for the Treatment of Influenza in Children
Retrieved on:
Friday, March 27, 2020
FDA, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Infectious diseases, RTT, Organic compounds, Chemical compounds, Antivirals, Genentech, Influenza, Baloxavir marboxil, Zanamivir, Influenza treatment, miniSTONE-2, BLOCKSTONE, Xofluza® (baloxavir marboxil), Genentech in Influenza, Genentech
Todays milestone brings us closer to providing single-dose Xofluza to children with influenza, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.
Key Points:
- Todays milestone brings us closer to providing single-dose Xofluza to children with influenza, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.
- We also look forward to working with the FDA to incorporate Xofluza as a preventive treatment following exposure to influenza.
- Xofluza tablets are currently approved in many countries around the world for the treatment of influenza types A and B.
- BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza.